PRLD

3.68

6.36% 0.22

Handel nachbörslich: 3.73 0.05 +1.36%

Prelude Therapeutics Inc (PRLD)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$3.46

Offen:

$3.51

24-Stunden-Volumen:

391.12K

Relative Volume:

1.14

Marktkapitalisierung:

$231.85M

Einnahmen:

$12.14M

Nettoeinkommen (Verlust:

$-99.50M

KGV:

-2.7185

EPS:

-1.3537

Netto-Cashflow:

$-56.37M

1W Leistung:

+19.87%

1M Leistung:

+13.93%

6M Leistung:

+152.05%

1J Leistung:

+445.19%

1-Tages-Spanne:

$3.48

$3.90

1-Wochen-Bereich:

$3.14

$3.90

52-Wochen-Spanne:

$0.6101

$4.22

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Firmenname

Prelude Therapeutics Inc

Sektor

Healthcare (1116)

Branche

Biotechnology (624)

Telefon

(302) 467-1280

Adresse

175 INNOVATION BOULEVARD, WILMINGTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-10-30

Neueste SEC-Einreichungen

PRLD's Discussions on Twitter

Compare PRLD vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PRLD Prelude Therapeutics Inc	3.68	217.99M	12.14M	-99.50M	-56.37M	-1.3537
VRTX Vertex Pharmaceuticals Inc	434.30	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	763.04	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.25	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.34	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.81	35.01B	606.42M	-1.28B	-997.58M	-6.403

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-09-19	Hochstufung	H.C. Wainwright	Neutral → Buy
2024-06-20	Herabstufung	Barclays	Equal Weight → Underweight
2024-03-13	Eingeleitet	JMP Securities	Mkt Outperform
2024-02-20	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-12-19	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2022-11-21	Herabstufung	BofA Securities	Neutral → Underperform
2022-09-09	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-07-29	Eingeleitet	Jefferies	Buy
2022-03-15	Herabstufung	BofA Securities	Buy → Neutral
2022-02-28	Herabstufung	Barclays	Overweight → Equal Weight
2021-10-08	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2021-07-27	Hochstufung	BofA Securities	Neutral → Buy
2021-04-26	Eingeleitet	H.C. Wainwright	Buy
2021-03-09	Eingeleitet	Barclays	Overweight
2020-11-20	Herabstufung	BofA Securities	Buy → Neutral
2020-10-20	Eingeleitet	BofA Securities	Buy
2020-10-20	Eingeleitet	Goldman	Neutral
2020-10-20	Eingeleitet	Morgan Stanley	Equal-Weight

Alle ansehen

Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten

Apr 02, 2026

Prelude Therapeutics Incorporated (PRLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Apr 02, 2026

PRLD Technical Analysis | Trend, Signals & Chart Patterns | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill

Apr 02, 2026

Apr 01, 2026

Prelude Therapeutics reports 2025 results and advances oncology pipeline - MSN

Apr 01, 2026

Mar 31, 2026

PRLD Technical Analysis & Stock Price Forecast - Intellectia AI

Mar 31, 2026

Mar 30, 2026

Rate Hike: Is Prelude Therapeutics Incorporated backed by strong institutional buying2026 Drop Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn

Mar 30, 2026

Mar 22, 2026

Marker Therapeutics (NASDAQ:MRKR) & Prelude Therapeutics (NASDAQ:PRLD) Financial Survey - Defense World

Mar 22, 2026

Mar 21, 2026

If You Invested $1,000 in Prelude Therapeutics Inc (PRLD) - Stock Titan

Mar 21, 2026

PRLD PE Ratio & Valuation, Is PRLD Overvalued - Intellectia AI

Mar 21, 2026

Mar 20, 2026

Value Recap: How do insiders feel about Prelude Therapeutics IncorporatedChart Signals & Community Consensus Trade Alerts - baoquankhu1.vn

Mar 20, 2026

Mar 17, 2026

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting - Yahoo Finance

Mar 17, 2026

Mar 16, 2026

Prelude Therapeutics Reports 2025 Results and Advances Oncology Pipeline - MyChesCo

Mar 16, 2026

Mar 13, 2026

Prelude Therapeutics Inc. Files Form 8-K with SEC – Company Information and Legal Exhibit Details (March 12, 2026) - Minichart

Mar 13, 2026

Prelude Therapeutics Establishes New ATM Equity Offering Facility - The Globe and Mail

Mar 13, 2026

Mar 12, 2026

Prelude Therapeutics files to offer up to $25 million in stock through Jefferies By Investing.com - Investing.com South Africa

Mar 12, 2026

Prelude Therapeutics files to offer up to $25 million in stock through Jefferies - Investing.com

Mar 12, 2026

Prelude Therapeutics 2025 Annual Report: Precision Oncology Pipeline, Business Strategy, and Regulatory Overview - Minichart

Mar 12, 2026

Mar 11, 2026

Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet

Mar 11, 2026

ADC Therapeutics SA (ADCT) Reports Wider Loss Q4 EPS Estimates by 85.1% - AlphaStreet

Mar 11, 2026

Prelude Therapeutics (NASDAQ:PRLD) Price Target Raised to $6.00 at Citizens Jmp - MarketBeat

Mar 11, 2026

Citizens Analyst Raises Price Target for Prelude Therapeutics (P - GuruFocus

Mar 11, 2026

Citizens raises Prelude Therapeutics price target on JAK2 potential By Investing.com - Investing.com Canada

Mar 11, 2026

Mar 10, 2026

Prelude Therapeutics (PRLD) Q4 Loss Per Share Narrows Challenging Longstanding Bearish Narratives - simplywall.st

Mar 10, 2026

PRLD: Pipeline refocused on JAK2 V617F and KAT6A, with strong funding and key Incyte partnership - TradingView

Mar 10, 2026

Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings - AlphaStreet

Mar 10, 2026

Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M - AlphaStreet

Mar 10, 2026